Majeed, T, de Simone, C, Famularo, G et al. · European journal of neurology · 1995 · DOI
This study examined carnitine, a substance that helps cells produce energy, in people with ME/CFS. Researchers found that while carnitine levels in the blood were normal, the levels inside immune cells were significantly lower in ME/CFS patients compared to healthy people. This finding suggests that ME/CFS patients might benefit from taking carnitine supplements to restore normal energy production.
This study provides early evidence of an energy metabolism defect specific to the cellular level in ME/CFS, which could explain the hallmark post-exertional symptom worsening. If carnitine deficiency is a consistent finding across tissues, it could lead to targeted supplementation strategies as a potential therapeutic intervention for ME/CFS.
This study does not establish whether carnitine deficiency is a cause or a consequence of ME/CFS. It also does not prove that carnitine supplementation will be effective or beneficial in ME/CFS patients, nor does it determine whether deficiency occurs in skeletal muscle or other tissues directly (only inferred from PBL findings). The small sample size and cross-sectional design limit causal inference.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.